Jenn Creel is the Chief Financial Officer of ADC Therapeutics.
Ms. Creel joined ADC Therapeutics from Celgene Corporation, where she most recently served as Franchise Chief Financial Officer and Corporate Vice President, Global Finance & Business Planning until the company’s acquisition by Bristol Myers Squibb. During her 11 years at Celgene, Ms. Creel held multiple finance positions of increasing responsibility, including Vice President of Finance, Hematology & Oncology, and Executive Director, Global Business Planning & Analysis. Earlier in her career, Ms. Creel held finance roles at Watson Pharmaceuticals, Inc. and Pfizer Inc.
She holds an MBA from the University of Virginia and a BA in Economics and French from The College of William and Mary.